Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment

Clinical Lymphoma & Myeloma
Antonio RuedaEmilio Alba

Abstract

Doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) chemotherapy alone is a viable option for the treatment of stage I/II Hodgkin's lymphoma. Among the main drawbacks for widespread acceptance of this therapy is the absence of available data on the post-salvage therapy course in patients with limited-stage disease who relapse after ABVD. This article focuses on the outcome of 11 limited-stage patients who relapsed after ABVD alone. After a clinical restaging, the patients received mantle-type radiation therapy (only if patients met these criteria: supradiaphragmatic disease in a single-node area, erythrocyte sedimentation rate < 30 mm per hour, and absence of B symptoms) or conventional salvage chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation. After a median follow-up of 64 months, 10 patients showed complete response and are still alive without disease progression. One patient showed refractory disease and died 9 months after relapse. This experiment entails the series with the longest follow-up in patients with limited-stage Hodgkin's lymphoma who relapsed after ABVD alone. The data seem to indicate that salvage therapy is capable of providing cure in most cases and lend ...Continue Reading

Citations

Oct 19, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A BarnesJ S Abramson
Jul 19, 2011·Journal of Experimental & Clinical Cancer Research : CR·Nizar M MhaidatAhmad N Aldaher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

The Cancer Journal
Fahd Quddus, James O Armitage
Critical Reviews in Oncology/hematology
B Desoize, J Jardillier
The Journal of Pathology
D B Longley, P G Johnston
Oncogene
Suresh V AmbudkarMichael M Gottesman
© 2022 Meta ULC. All rights reserved